... declines from COVID-19 products and withstand competition from generics. Investors will pay close attention to sales of the flagship immunotherapy, Keytruda, and the Gardasil vaccine. Also of focus will be comments about progress in new drug development (pipeline) that could help in future replenishments for expiring patent drugs. If financial results exceed forecasts (e.g., due to unexpectedly high vaccine or new drug sales) or the company raises its annual guidance, MRK shares may receive support. Conversely,...